How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

KRAS activating mutations as predictors of susceptibility to Hsp90-inhibitor-treatment

Organization name

Max-Planck-Innovation GmbH

Profile

Background

The Heat shock protein 90 (Hsp90) is part of a multichaperone complex involved in posttranslational folding of client proteins. A lot of these client proteins play essential roles in tumorigenesis. However, it is still largely unknown how Hsp90 can recognize structurally unrelated client proteins and which client protein plays an essential role in a specific tumor type. Once known, such a client-oncoprotein might be used as a marker to stratify the patient population prior to treatment with an Hsp90-inhibitor and to predict responsiveness of those patients.

Technology

Scientists from the Max Planck Institute for Neurological Research in Cologne and the Medical Faculty of the University of Cologne have developed a genomics approach to identify genetic lesions in tumor cells associated with therapeutically relevant oncogene dependency:The genomes of a large panel of human non-small cell lung cancer (NSCLC) cell lines were shown to be highly representative of those of of primary human NSCLC tumors.Using cell-based compound screening coupled with diverse computational approaches to integrate orthogonal genomic and biochemical data sets, enabled the identification of molecular and genomic predictors of therapeutic response to clinically relevant compounds.Using this approach, it could be shown that KRAS (v-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog) activating mutations confer enhanced Hsp90 dependency. Cell culture data were validated in mice with KRAS-driven lung adenocarcinoma, as these mice exhibited dramatic tumor regression when treated with an Hsp90 inhibitor.

Patent Information

A priority application was filed on August 2009. Meanwhile a worldwide application is pending.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries